|
1
|
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.
|
Eur J Cancer
|
2008
|
1.95
|
|
2
|
Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
|
J Urol
|
2007
|
1.73
|
|
3
|
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.
|
Cancer Treat Rev
|
2010
|
1.43
|
|
4
|
Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.
|
BJU Int
|
2007
|
1.39
|
|
5
|
Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells.
|
Immunology
|
2005
|
1.25
|
|
6
|
Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.
|
BJU Int
|
2008
|
1.17
|
|
7
|
Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
|
Mol Cancer Res
|
2008
|
1.07
|
|
8
|
Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2013;63:998-1008.
|
Eur Urol
|
2013
|
1.06
|
|
9
|
Com-1/p8 acts as a putative tumour suppressor in prostate cancer.
|
Int J Mol Med
|
2006
|
0.94
|
|
10
|
Robotic or open radical cystectomy, which is safer? A systematic review and meta-analysis of comparative studies.
|
J Endourol
|
2014
|
0.93
|
|
11
|
Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?
|
Int J Mol Med
|
2006
|
0.92
|
|
12
|
Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer.
|
Exp Mol Pathol
|
2013
|
0.87
|
|
13
|
Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.
|
Clin Immunol
|
2006
|
0.86
|
|
14
|
HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells.
|
Urol Oncol
|
2007
|
0.84
|
|
15
|
Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway.
|
J Urol
|
2009
|
0.82
|
|
16
|
Safety and feasibility of laparoscopic radical cystectomy for the treatment of bladder cancer.
|
J Endourol
|
2013
|
0.81
|
|
17
|
Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
|
Int Immunol
|
2005
|
0.81
|
|
18
|
Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells.
|
Mol Cell Biochem
|
2010
|
0.80
|
|
19
|
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
|
Int J Oncol
|
2007
|
0.79
|
|
20
|
Management of lower urinary tract symptoms in men.
|
Br J Hosp Med (Lond)
|
2013
|
0.75
|
|
21
|
Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87-99.
|
Eur Urol
|
2009
|
0.75
|
|
22
|
A role for STEAP2 in prostate cancer progression.
|
Clin Exp Metastasis
|
2014
|
0.75
|